Brand Institute, announced its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide. Bavdegalutamide, also referred to as ARV-110, was published as a recommended INN in April of 2022. The product was granted fast-track designation by the FDA in May of 2019 for the treatment of metastatic castration-resistant prostate cancer.